bioRxiv (Cold Spring Harbor Laboratory)
June 17, 2019
Tetiana Kardash, Dmitry Rodin, Michael Kirby et al.
preprint
ABSTRACT The effects of cannabis reported by users range from experiences of euphoria and anxiolytic effects to paranoia, anxiety, and increased risk of depression. Attempts to reconcile the apparent contradictions in user response have not been conclusive. Here, we utilized selectively-bred stress-resilient socially dominant (Dom) and stress-sensitive socially submissive (Sub) mice to...
Sage Open
June 14, 2019
Siobhan Lynch, Marie-Louise Gander, Ananda Nahar et al.
The benefits of mindfulness for a variety of clinical and nonclinical populations are well established and there is growing interest in the potential of mindfulness in higher education. This article reports on the results from a randomized wait-list controlled study of Mindfulness-Based Coping With University Life (MBCUL), an adaption of Mindfulness-Based Stress Reduction (MBSR) for university...
June 11, 2019
Daniel W Grupe, Chad Mcgehee, Christine E. Smith et al.
BACKGROUND. Police officers are exposed daily to high levels of organizational and operational stressors that have a negative impact on health and well-being outcomes. This population has elevated rates of cardiovascular disease, sleep disorders, symptoms of depression and post-traumatic stress disorder (PTSD), and suicide. Although there are few empirically supported effective stress reduction...
Building Healthy Academic Communities Journal
June 7, 2019
Samantha Whitford, Keith Warren
Background: Meditation is likely to be a useful intervention for anxiety and depression, and is increasingly common as a clinical intervention and informal practice among university students. However, meditation dropout rates are high, and it is likely that perceived barriers to meditation play a role. While neuroticism is known to predict dropout, there has been no study relating personality...
Frontiers in Psychology
June 4, 2019
Raíssa Nóbrega de Almeida, Ana Cecília de Menezes Galvão, Flávia Santos Da Silva et al.
173 citations
Serotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as suggested in a recent randomized controlled trial with ayahuasca for treatment-resistant depression. Preclinical and clinical studies have suggested that serum brain-derived neurotrophic factor (BDNF) levels increase after treatment with serotoninergic antidepressants, but the exact role of BDNF as a...
Biological Psychiatry
June 3, 2019
Anya K. Bershad, Scott T. Schepers, Michael P. Bremmer et al.
176 citations
BackgroundNumerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 μg) positively bias emotion processing. Yet, the effects of such...
Mindfulness
June 2019
Cameron L. Neece, Neilson Chan, Keith Klein et al.
Parents of children with developmental delays (DD) report elevated mental health difficulties compared to parents of children with typical development, which appear largely associated with child behavior problems. Latino parents of children with DD may experience heightened risk for poor mental health outcomes due additional stressors associated with minority status. Mindfulness-Based Stress...
Complementary Therapies in Medicine
June 1, 2019
Lu Shi, Ralph S Welsh, Snehal Lopes et al.
Mindful walking is a meditation practice that combines physical activity and mindfulness practice. Some mindful walking interventions expect four weeks of attendance (as compared with the traditional 8-week models of mindfulness-based interventions, or MBIs), a practice that could make MBIs more accessible to working-age adults. This study examined whether a 4-week mindful walking intervention...
Pharmacology, Biochemistry, and Behavior
June 1, 2019
Lijia Chang, Kai Zhang, Yaoyu Pu et al.
174 citations
The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with depression although intranasal use of (R,S)-ketamine in ketamine abusers is popular. In March 5, 2019, nasal spray of (S)-ketamine for treatment-resistant depression was approved as a new antidepressant by the US Food Drug Administration....
ChemBioChem
May 31, 2019
Janis Fricke, Alexander M. Sherwood, Robert B. Kargbo et al.
38 citations
Abstract Psilocybin and its direct precursor baeocystin are indole alkaloids of psychotropic Psilocybe mushrooms. The pharmaceutical interest in psilocybin as a treatment option against depression and anxiety is currently being investigated in advanced clinical trials. Here, we report a biocatalytic route to synthesize 6‐methylated psilocybin and baeocystin from 4‐hydroxy‐6‐methyl‐ l...